3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
20
Carcinoma, Renal Cell
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
6
Neoplasms
4
Biliary Tract Neoplasms
4
Neuroendocrine Tumors
3
Melanoma
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Interventions
Fluorouracil
13
pembrolizumab
12
Paclitaxel
12
Oxaliplatin
12
Leucovorin
9
Carboplatin
9
Capecitabine
8
Trastuzumab
7
Nivolumab
7
Cisplatin
7
Radiotherapy
6
Radiation
6
Taxes
5
Esophagectomy
5
Drug Therapy
5
Surgical Procedures, Operative
4
Specimen Handling
4
Irinotecan
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Radiotherapy, Intensity-Modulated
3
Proton Therapy
3
Immunotherapy
3
zanidatamab
2
ulixertinib
2
trastuzumab biosimilar HLX02
2
relatlimab
2
durvalumab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
lenvatinib
×
90 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled